Karius

Company profile

About Karius

Karius is revolutionizing infectious disease diagnostics through advanced metagenomic sequencing technology. The company leverages the power of clinical metagenomics to detect microbial cell-free DNA (mcfDNA) circulating throughout the body from pathogens that may cause infections. Their vision is to create a world where every patient gets a clear and timely diagnosis. Karius offers two primary diagnostic products: Karius Spectrum, a blood test that detects over 1,000 fungi, bacteria, DNA viruses, and parasites associated with deep-seated and difficult-to-diagnose systemic infections; and Karius Focus | BAL, a bronchoalveolar lavage fluid-based test designed for detection of over 500 pathogens associated with lung infections. Both tests are powered by the Karius Helion platform, which combines proprietary chemistry, a continuously updated clinical-grade database of over 20,000 microbial references, and advanced machine learning algorithms. The company serves healthcare providers treating high-risk hospitalized patients, particularly immunocompromised individuals facing pneumonia, febrile neutropenia, invasive fungal infections, endocarditis, and fever of unknown origin. Karius provides results typically within one day after sample receipt, compared to conventional methods that can take days to weeks. The company's CLIA-certified and CAP-accredited laboratory is based in Redwood City, California, and they have established partnerships with leading institutions including Mayo Clinic Laboratories to expand access to their diagnostic solutions.

Company description · Karius official website